Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial entities : Johnson & johnson save search
AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
Published: 2024-04-15 (Crawled : 12:00) - biospace.com/
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
avb-101 first dementia for trial
Global $4.1 Billion Clinical Trial Supplies Market Report 2024-2034 - Emerging Markets Catalyzing Growth in Clinical Trial Supplies
Published: 2024-03-26 (Crawled : 17:00) - prnewswire.com
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
ICLR | $288.625 -1.1% 73K
|
Health Technology
|
| O: 0.46%
H: 0.65%
C: -0.43%
report global trial growth market
Oncology Precision Medicine Market Research, Industry Trends and Global Forecasts, 2035 - Rising Partnership and Clinical Trial Activity Reflect Growing Interest in the Market
Published: 2024-03-15 (Crawled : 15:00) - prnewswire.com
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: -1.58%
H: 0.0%
C: 0.0%
partnership precision global trends growing trial market
Mezzion Pharmaceuticals Announces Dr. Rahul Rathod of Boston Children's Hospital and Harvard Medical School as the Global Principal Investigator for the Confirmatory Pivotal Phase 3 Trial FUEL-2
Published: 2024-03-01 (Crawled : 23:00) - prnewswire.com
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
| Email alert
Add to watchlist
hospital pharmaceuticals global medical trial
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
Published: 2023-12-15 (Crawled : 12:30) - globenewswire.com
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: -0.39%
H: 0.0%
C: 0.0%
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: -4.44%
H: 0.0%
C: 0.0%
ACIU | $2.38 8.8K
|
Health Technology
|
| O: -1.62%
H: 9.04%
C: 7.4%
disease active alzheimer’s immunotherapy trial
BillionToOne Announces Global Collaboration to Provide its UNITY Fetal Antigen™ Clinical Trial Assay in Johnson & Johnson Phase 3 Clinical Trial of Nipocalimab in Hemolytic Disease of the Fetus and Newborn
Published: 2023-12-12 (Crawled : 21:00) - biospace.com/
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: 0.1%
H: 0.0%
C: 0.0%
disease global collaboration trial
How Companies Are Upping Diversity Among Clinical Trial Participants
Published: 2023-10-18 (Crawled : 05:00) - biospace.com/
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: -0.83%
H: 0.35%
C: -1.72%
companies trial
Lilly’s Mirikizumab Shows Long-Term Remission in Phase III Crohn’s Trial
Published: 2023-10-12 (Crawled : 15:30) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.97%
H: 0.0%
C: 0.0%
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: -1.87%
H: 0.0%
C: 0.0%
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: 0.54%
H: 0.0%
C: 0.0%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: 0.0%
trial
Anthos Stops Mid-Stage Atrial Fibrillation Trial Due to ‘Unprecedented’ Efficacy
Published: 2023-09-18 (Crawled : 15:30) - biospace.com/
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: 0.48%
H: 0.0%
C: 0.0%
trial
AbbVie’s Skyrizi Outperforms J&J’s Stelara in Late-Stage Crohn’s Disease Trial
Published: 2023-09-13 (Crawled : 13:30) - biospace.com/
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: 1.05%
H: 0.73%
C: 0.14%
disease skyrizi trial stelara
Lynk Pharmaceuticals Announces Positive Topline Data from Phase II Clinical Trial of LNK01001 in the Treatment of Ankylosing Spondylitis
Published: 2023-08-23 (Crawled : 14:00) - biospace.com/
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: -0.25%
H: 0.0%
C: 0.0%
lnk0100 positive treatment pharmaceuticals topline trial
FDA Lifts Partial Hold on Arcellx’s Multiple Myeloma Trial After Patient Death
Published: 2023-08-15 (Crawled : 14:20) - biospace.com/
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: -0.82%
H: 0.0%
C: 0.0%
fda trial
PAN-TB Collaboration Announces the Start of a Phase 2 Clinical Trial to Evaluate Two Novel Tuberculosis Treatment Regimens
Published: 2023-08-09 (Crawled : 17:00) - biospace.com/
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: 0.0%
start treatment collaboration trial phase 2
Lynk Pharmaceuticals Announced Positive Topline Data from Phase II Clinical Trial of LNK01001 in the Treatment of Atopic Dermatitis
Published: 2023-08-09 (Crawled : 12:00) - prnewswire.com
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: 0.0%
lnk0100 dermatitis positive treatment pharmaceuticals topline trial
J&J’s Protagonist-Licensed Psoriasis Drug Falls Short in Phase II Trial
Published: 2023-07-03 (Crawled : 00:00) - biospace.com/
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: -0.71%
H: 0.03%
C: -0.6%
drug psoriasis trial
Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)
Published: 2023-06-23 (Crawled : 21:00) - globenewswire.com
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
| Email alert
Add to watchlist
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
| Email alert
Add to watchlist
obesity pharma trial
FDA Hold on Arcellx’s Multiple Myeloma Cell Therapy Trial After Patient Death
Published: 2023-06-20 (Crawled : 15:00) - biospace.com/
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: 0.02%
H: 0.64%
C: -0.08%
fda cell trial therapy
ANeuroTech receives IND approval from the FDA for pivotal Phase IIIB trial of adjunctive anti-depression drug, ANT-01
Published: 2023-06-05 (Crawled : 23:00) - biospace.com/
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: -0.14%
H: 1.21%
C: 1.0%
ant-01 fda approval trial
Topas Therapeutics Initiates Phase 2a Clinical Trial for TPM502 in Celiac Disease; Appoints Chief Business Officer and Chief Operating Officer
Published: 2023-05-25 (Crawled : 10:00) - biospace.com/
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: -0.39%
H: 0.15%
C: -1.05%
tpm502 business trial therapeutics
Levy Konigsberg Files Motion to Consolidate 22 Talc Mesothelioma Lawsuits for Trial Against Johnson & Johnson
Published: 2023-04-25 (Crawled : 04:00) - prnewswire.com
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: 0.38%
H: 0.63%
C: 0.53%
FRBA | News | $12.405 2.35% 18K
|
Finance
|
| O: -0.73%
H: 2.41%
C: -0.94%
trial
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.054 50.0% 290M
|
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
NVFY | $2.71 28.44% 31M
|
Consumer Durables
ZCMD | $1.86 28.28% 29M
|
Commercial Services
RWOD | $10.08 26.05% 5.6M
|
n/a
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
TPET | $0.4001 22.02% 35M
|
n/a
SRFM 4 | $0.6 21.29% 850K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.